Search results for: Multi-Indication Medicines
Filter search results
5 Things You Should Do with EQ-5D Data
29 January 2016
…‘utilities’) used in the calculation of QALYs (quality adjusted life years), EQ-5D has become the cornerstone of health technology appraisal (HTA), affecting important decisions about access to new medicines. But…
What Drives Variations in Relative Effectiveness Across Countries?
31 May 2016
…for exploring the use of a health production function approach to better understand the impact of new medicines and devices for improvements in health outcomes. Moreover, the health production function…
The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics
5 July 2016
…analysis broadens the use of the term beyond predicting response to specific medicines. For the Joint OHE/EPEMED press rel ease The White Paper: The Value of Knowing and Knowing the…
New Publication: Assessing Evidence and Access Associated with NICE HTA Decisions Categorised as “Recommended in Line with Clinical Practice”
6 January 2017
…and ‘optimised’ recommendations. In these instances restrictions are being placed on the use of innovative medicines, and reported in a way that is not readily transparent that this is the…
The Office of Health Economics Becomes a Registered Charity
3 February 2017
…was known about R&D and investment, how to measure quality of life or health status and whether medicines represented value for money. OHE was set up to answer these questions….
OHE at ISPOR Boston 2017: Presentations and Posters
4 July 2017
…the European Union via the centralised procedure (coordinated by the European Medicines Agency); many health care systems in Europe then evaluate new technologies according to their effectiveness and cost effectiveness….
What do Pharmaceuticals Really Cost in the Long Run?
6 October 2017
…Medicines Files for the period ranging from 1996 to 2013. Defining the year of Loss of Exclusivity (LOE) as the first year that a generic National Drug Code was used…
Opportunities for Utilising ‘Real World Data’ in South Korea
20 October 2017
OHE publishes a report assessing the capacity in South Korea for the collection and use of real-world data in health care. Real world data (RWD) is information collected from a…
Pricing and Paying for Cures: Early Experience with HTA of Gene Therapy in the USA
28 February 2019
…and Cures: A Discrete Choice Experiment. OHE Consulting Report, London: Office of Health Economics. RePEc. Marsden, G. and Towse, A., 2017. Exploring the Assessment and Appraisal of Regenerative Medicines and Cell…